Clinical and imaging characteristics of non-manifest LRRK2 and GBA carriers: The PPMI cohort
Objective: To examine baseline clinical and dopamine transporter (DAT) imaging characteristics in a cohort of non-manifest carriers (NMC) of GBA and LRRK2 compared to healthy…Experimental model of developing of Parkinson’s disease
Objective: Analyzing the reserpine model of Parkinsonian syndrome Background: There are several experimental models of Parkinson's disease: reserpine, methamphetamine, 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine - substances that…A Unified Staging System for Prodromal and Manifest Huntington’s disease
Objective: To develop an integrated staging methodology for Prodromal and Manifest Huntington’s disease (HD). Background: Once HD is diagnosed clinically (also known as, motor-onset/manifest), HD…A life-threatening case of Anti-IgLON5 disease
Objective: To present a case of anti-IgLON5 disease with life-threatening respiratory complications. Background: Anti-IgLON5 disease is a little known CNS disorder characterized by non-REM and…Acute hemichorea in patient of uncontrolled type 2 diabetes mellitus; a case report with characteristic imaging
Objective: chorea is a rare complication of uncontrolled type 2 diabetes . we report a case of hyperglycemia, due to uncontrolled type 2 diabetes, presented…Generalized chorea in a patient with isolated leukocytosis and JAK2V617F mutation: A case report
Objective: To describe late-onset generalized chorea in a patient found to have the JAK2V617F mutation without polycythemia vera. Background: Polycythemia vera (PV) is well-known to…Elevated serum α-synuclein levels in Huntington’s disease patients
Objective: To investigate serum α-synuclein levels in Huntington’s disease (HD) patients. Background: HD is a heredodegenerative disease caused by mutations in HTT coding for huntingtin…Parallel evaluation of mutant huntingtin and neurofilament light in Huntington’s disease
Objective: To assess cerebrospinal fluid (CSF) mutant Huntingtin (mHTT), and CSF and plasma neurofilament light (NfL) in Huntington’s disease (HD). Background: HD is a progressive…Neurofilament light protein: An emerging clinical and translational biofluid biomarker for Huntington’s disease
Objective: To investigate whether neurofilament light protein (NfL) a potential prognostic marker of neurodegeneration with Huntington’s disease. Background: NfL, a component of the axonal cytoskeleton,…Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease
Objective: The present study examined the potential therapeutic effects of CA against 3-nitropropionic acid (3-NP)-induced oxidative stress in a rat model of HD and explored…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- Next Page »
